Navigation Links
BioMarin Receives Positive Opinion from European Regulatory Authorities for Expanded Biologics Manufacturing Facility
Date:12/19/2011

approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, amifampridine phosphate (3,4-diaminopyridine phosphate), which is currently in Phase III clinical development for the treatment of LEMS in the U.S., PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking StatementThis press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of revenue and sales related to Naglazyme, Kuvan, Firdapse, and Aldurazyme; the financial performance of the BioMarin as a whole; the timing of BioMarin's clinical trials of GALNS, Firdapse, PEG-PAL, BMN-673, BMN-701 and other product candidates; the continued clinical development and commercialization of Aldurazyme, Naglazyme, Kuvan, Firdapse, and its product candidates; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Naglazyme, Kuvan, and Fir
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Highlights from BioMarins Research & Development Day
2. BioMarin Announces Buy Back of Naglazyme Royalties From Adelaide Health Authority
3. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
4. BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility
5. BioMarin to Host a Research and Development Day on December 8th
6. BioMarin Announces Third Quarter 2011 Financial Results
7. BioMarin to Present at the UBS Global Life Sciences Conference
8. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
9. BioMarin to Present at the Baird Health Care Conference
10. BioMarin to Present at the Wedbush Life Sciences Conference
11. BioMarin Announces Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- CryoLife, Inc. (NYSE: CRY ), a leading ... and vascular surgery, announced today that James Patrick ... been elected to the Company,s Board of Directors, effective ... , Executive Chairman of CryoLife, stated, "Since joining the Company ... leader who is well positioned to maximize CryoLife,s potential. ...
(Date:10/22/2014)... SAN DIEGO , Oct. 21, 2014 /PRNewswire/ ... announced today the latest genomics research centers to ... the Salk Institute, the National Cancer Institute (NCI), ... National Sequencing Center). Before Irys, obtaining a comprehensive ... because next generation sequencing (NGS) does not deliver ...
(Date:10/22/2014)... Calif. , Oct. 21, 2014 Influenza will ... flu-associated deaths in the United States ... viruses are thought to spread is from person to person ... Ebola has a serve way of death, but kills much ... Ebola is also done by human fluids including sweat, saliva, ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2
... Inc. announced today that it has raised $19.2 million ... GBS Venture Partners and BioPacificVentures participated in the round. ... from additional investors in a second closing, scheduled for ... us to take essential steps for the development of ...
... Sanofi-aventis (EURONEXT: SAN and NYSE: ... into a multi-year research collaboration agreement through the Stanford ... collaborative and innovative research projects in the early phases ... Dr. Paul Chew, Senior Vice President, U.S. Chief Science ...
Cached Medicine Technology:CoDa Therapeutics Closes $19 Million Series B Financing Round 2CoDa Therapeutics Closes $19 Million Series B Financing Round 3CoDa Therapeutics Closes $19 Million Series B Financing Round 4Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research 2Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research 3
(Date:10/22/2014)... October 22, 2014 During the Western ... water supply runs dangerously low, Southern Oregon’s water is ... rivers, despite the lowest mountain snow pack on record ... summer and early autumn.* That was the observation of ... new book “Hiking Southern Oregon,” during an interview with ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In ... in the face, it certainly can be difficult to choose ... an extra favor by doing it the healthy way? Set ... listen to your body, exercise regularly, and choose foods with ... losing weight; you need to exercise more and eat less. ...
(Date:10/22/2014)... of Prussia, PA (PRWEB) October 22, 2014 ... is recognized as an industry leader with over 25 ... award winning team leader in the areas related to ... addition, Mr. Carlson is an Editorial Advisory Board member ... Healthcare Council Educator. Blue Fin Group is a ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... (IVF) are only about half as likely as white women ... research indicates, and the racial disparity persists even when donor ... of white patients became pregnant after IVF, compared to about ... IVF cycles over two years to tease out the impact ...
(Date:10/22/2014)... By Maureen Salamon ... -- A crucial part of conventional in vitro fertilization (IVF) ... can instead take place in a device inside the vagina, ... Colombia contend that the device, called an INVOcell, might sharply ... could also make the technology more accessible to those who ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... The U.S. Pharmacopeial (USP) Convention is pleased ... from the Cooperation on International Traceability in Analytical ... on Metrology in Chemistry in 2008. , USP,s ... Reference Standards Program: Certified Reference Materials," was published ...
... NovoCure Ltd. presented results yesterday evaluating the Novo-TTF ... trial that showed the device enhanced the efficacy ... multiforme (GBM) patients. When used in combination with ... that uses low intensity alternating electric fields to ...
... QC, Nov. 24 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; ... will host a webcast presentation on Tuesday, December 16, ... senior management team will discuss the product profile, clinical ... novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist ...
... 24 Availity, L.L.C. was,recognized as the ... Site in the,Business/Process Improvement Applications or Products ... Conference November 11 in Orlando, Florida. The,eHealthcare ... & Trends,a leading internet publication and online ...
... new treatments, researchers say , , MONDAY, Nov. 24 (HealthDay News) ... system and blood vessels may contribute to epileptic seizures, new ... case, such interactions may be a target for new treatments ... the Nov. 23 issue of Nature Medicine . , ...
... 24 Aurora Health Care Ventures has been,granted ... Inc. for Aurora Pharmacy and a health-oriented retail ... The accreditation applies to Aurora,s 130 retail pharmacies, ... retail store inside Aurora,St. Luke,s Medical Center in ...
Cached Medicine News:Health News:Studies show novel device may enhance chemotherapy treatment in brain tumors 2Health News:Studies show novel device may enhance chemotherapy treatment in brain tumors 3Health News:Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder 2Health News:Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder 3Health News:Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder 4Health News:Availity Achieves 2008 eHealthcare Leadership Award 2Health News:Clue to Cause of Epileptic Seizures Discovered 2Health News:Accreditation Commission for Health Care Accredits Aurora Pharmacy Sites, Retail Store 2
Sealing Mat for 96-well PCR Plate, Natural...
MicroAmp Full Plate Covers, which are manufactured from PCR-compatible rubber, are non-sterile, autoclavable and guaranteed reusable up to five times....
Omniseal TD mat. Reusable rubber mat for sealing PCR plates. 5 pk....
... Heat Sealing Film each provide 100% evaporation prevention ... sample storage. In automated procedures the aluminum-coated foil ... The Heat Sealing Film is transparent and allows ... Sealing Foil is removed by simply peeling it ...
Medicine Products: